Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms حسب Farman M. Abbasi (22318766)

"…We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …"

Role of MIB2 and CAMK2 in FAT1-depndent regulation of YAP/TAZ protein levels and YAP/TAZ nuclear localization. حسب Rui Li (4631)

A proposed model for citrus tristeza virus (CTV) p20-mediated RNA silencing suppression. حسب Yongle Zhang (11355546)

Results of longitudinal analysis of mental health in HCWs. حسب A. H. Ayesha Lavell (16734002)

Characteristics of households participating in the SchistoBreak study in Pemba, Tanzania. حسب Lydia Trippler (10136316)

Spatial patterns of nodal module overlap (i.e., nodal entropy) for different network analysis strategies and their relationships with the main results. حسب Tianyuan Lei (19683861)

Patients’ demographics and clinical parameters. حسب Zi-Rong Chen (9227618)

"…Univariate GEE showed that a larger AL elongation in the initial 4 months was significantly associated with AL changes at 6 months (β = 0.354, <i><i>P</i></i> = 0.020, 6 ~ 12 months period from baseline) and 12 months (β = 0.560, <i><i>P</i></i> = 0.045, 6 ~ 18 months period from baseline) after that period in all myopic eyes.…"

Inhibition of ferroptosis alleviated the expression of hepatic حسب Haoyang Zhang (1706815)

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. حسب A. H. Ayesha Lavell (16734002)

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. حسب Hammad Ismail (4227988)

The performance of eigenvectors of the covariance matrix in a model with more complex population structure. حسب Joshua G. Schraiber (8027060)

Fig 4 - حسب Marjo K. Hytönen (8522271)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Baseline characteristics of cases and controls. حسب Soo Min Ahn (10333246)

"…Current exposure to sulfasalazine (aOR: 0.79, 95% CI: 0.65–0.97) and hydroxychloroquine (aOR: 0.83, 95% CI: 0.72–0.96) was associated with a decreased risk of stroke, while current exposure to glucocorticoids (aOR: 1.71, 95% CI: 1.46–2.00) and tocilizumab (aOR: 3.47, 95% CI: 1.70–7.08) was related to an increased risk of stroke.…"

Label-Free Quantitative Proteomic Analysis Reveals the Effects of Biogenic Silver Nanoparticles on Fusarium keratoplasticum and Their Therapeutic Potential in Galleria mellonella L... حسب Glaucia Rigotto-Caruso (22057974)

"…This study evaluated the antifungal activity and molecular effects of biogenic silver nanoparticles (AgNPs) synthesized using the culture filtrate of Epicoccum nigrum against Fusarium keratoplasticum, a highly resistant fungal species. AgNPs exhibited strong antifungal activity, with a MIC₅₀ of 1.79 μg/mL and 92.85% growth inhibition at 5.92 μg/mL. …"